What's breaking now, across thousands of outlets.
The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a likely candidate to receive reverse merger interest.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
(MedPage Today) -- The association between maternal influenza infection during pregnancy and neuropsychiatric disorders in children didn't hold up in sibling comparisons, according to a…
In early-stage cervical cancer, radical hysterectomy is an established treatment. The operation can be performed either through open surgery or robot-assisted minimally invasive surgery.
[Shabelle] Mogadishu -- Somalia's cabinet has approved measures to prepare for a possible Ebola outbreak and formed a six-ministry committee to coordinate the government's response, the government…
The season usually starts in October or November. But some western states, including California, Washington, Alaska and Hawaii, began seeing a rise in flu cases as early as August
Endeavor BioMedicines said its treatment for a chronic lung disease succeeded in a mid-stage test, claiming the drug had the potential to reverse the course of idiopathic pulmonary fibrosis in a ...
Plus news about ADC Therapeutics, Atrium Therapeutics, Bristol Myers, Novartis and Pfizer. Biohaven partners with Ono: Tokyo-based Ono Pharmaceutical has agreed to pay Biohaven $80 million upfront to…
